Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (661-670 of 993) with videos related to

Pageof 100
Sort By:
Urologic Oncology|February 23, 2013
Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcomeFaysal A Yafi, Simon Tanguay, Ricardo Rendon, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
European Urology Oncology|October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel TrialNoel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
Urologic Oncology|October 12, 2024
Critical care therapy and in-hospital mortality after radical nephroureterectomy for nonmetastatic upper urinary tract carcinomaFrancesco Di Bello, Carolin Siech, Mario de Angelis, et al.
Journal of Racial and Ethnic Health Disparities|June 13, 2026
Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European AmericansMaximilian Filzmayer, Federico Polverino, Michele Petix, et al.
Urologic Oncology|July 11, 2022
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy coreBenedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, et al.
Seminars in Oncology|May 24, 2022
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumabRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
The Lancet. Oncology|November 7, 2022
Intra-individual comparison of <sup>18</sup>F-sodium fluoride PET-CT and <sup>99m</sup>Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trialFrançois Bénard, Sara Harsini, Don Wilson, et al.
European Urology Oncology|November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel StudyAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
European Urology Focus|August 2, 2022
Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial NephrectomyGabriele Sorce, Benedikt Hoeh, Lukas Hohenhorst, et al.
Pageof 100

Showing results (661-670 of 993) with videos related to

Sort By:
Pageof 100
Urologic Oncology|February 23, 2013
Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcomeFaysal A Yafi, Simon Tanguay, Ricardo Rendon, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
European Urology Oncology|October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel TrialNoel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
Urologic Oncology|October 12, 2024
Critical care therapy and in-hospital mortality after radical nephroureterectomy for nonmetastatic upper urinary tract carcinomaFrancesco Di Bello, Carolin Siech, Mario de Angelis, et al.
Journal of Racial and Ethnic Health Disparities|June 13, 2026
Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European AmericansMaximilian Filzmayer, Federico Polverino, Michele Petix, et al.
Urologic Oncology|July 11, 2022
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy coreBenedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, et al.
Seminars in Oncology|May 24, 2022
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumabRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
The Lancet. Oncology|November 7, 2022
Intra-individual comparison of <sup>18</sup>F-sodium fluoride PET-CT and <sup>99m</sup>Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trialFrançois Bénard, Sara Harsini, Don Wilson, et al.
European Urology Oncology|November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel StudyAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
European Urology Focus|August 2, 2022
Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial NephrectomyGabriele Sorce, Benedikt Hoeh, Lukas Hohenhorst, et al.
Pageof 100